These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 25058845

  • 1. Long-acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium.
    Pepin JL, Cockcroft JR, Midwinter D, Sharma S, Rubin DB, Andreas S.
    Chest; 2014 Dec; 146(6):1521-1530. PubMed ID: 25058845
    [Abstract] [Full Text] [Related]

  • 2. A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD.
    Bhatt SP, Dransfield MT, Cockcroft JR, Wang-Jairaj J, Midwinter DA, Rubin DB, Scott-Wilson CA, Crim C.
    Int J Chron Obstruct Pulmon Dis; 2017 Dec; 12():351-365. PubMed ID: 28176907
    [Abstract] [Full Text] [Related]

  • 3. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk.
    Covelli H, Pek B, Schenkenberger I, Scott-Wilson C, Emmett A, Crim C.
    Int J Chron Obstruct Pulmon Dis; 2016 Aug; 11():1-12. PubMed ID: 26730183
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
    Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, Tabberer M, Harris S, Church A.
    Lancet Respir Med; 2014 Jun; 2(6):472-86. PubMed ID: 24835833
    [Abstract] [Full Text] [Related]

  • 7. Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease.
    Matera MG, Capuano A, Cazzola M.
    Expert Rev Respir Med; 2015 Feb; 9(1):5-12. PubMed ID: 25482512
    [Abstract] [Full Text] [Related]

  • 8. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.
    Bremner PR, Birk R, Brealey N, Ismaila AS, Zhu CQ, Lipson DA.
    Respir Res; 2018 Jan 25; 19(1):19. PubMed ID: 29370819
    [Abstract] [Full Text] [Related]

  • 9. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
    Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Sanford L, Lettis S, Crim C, Calverley PM.
    Lancet Respir Med; 2013 May 25; 1(3):210-23. PubMed ID: 24429127
    [Abstract] [Full Text] [Related]

  • 10. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.
    Martinez FJ, Boscia J, Feldman G, Scott-Wilson C, Kilbride S, Fabbri L, Crim C, Calverley PM.
    Respir Med; 2013 Apr 25; 107(4):550-9. PubMed ID: 23332861
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT.
    Marín JM, Mateos L, Roldán J, Echave-Sustaeta JM, Pascual-Guardia S, Pardo MV, Velasco B, Jones CE, Kilbride S, Lipson DA.
    Ther Adv Respir Dis; 2020 Apr 25; 14():1753466620963021. PubMed ID: 33121372
    [No Abstract] [Full Text] [Related]

  • 12. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD.
    Agustí A, de Teresa L, De Backer W, Zvarich MT, Locantore N, Barnes N, Bourbeau J, Crim C.
    Eur Respir J; 2014 Mar 25; 43(3):763-72. PubMed ID: 24114969
    [Abstract] [Full Text] [Related]

  • 13. Fluticasone furoate (FF)/vilanterol (100/25 mcg or 200/25 mcg) or FF (100 mcg) in persistent asthma.
    Bernstein DI, Bateman ED, Woodcock A, Toler WT, Forth R, Jacques L, Nunn C, O'Byrne PM.
    J Asthma; 2015 Mar 25; 52(10):1073-83. PubMed ID: 26291137
    [Abstract] [Full Text] [Related]

  • 14. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
    Siler TM, Nagai A, Scott-Wilson CA, Midwinter DA, Crim C.
    Respir Med; 2017 Feb 25; 123():8-17. PubMed ID: 28137501
    [Abstract] [Full Text] [Related]

  • 15. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.
    Stynes G, Svedsater H, Wex J, Lettis S, Leather D, Castelnuovo E, Detry M, Berry S.
    Respir Res; 2015 Feb 15; 16(1):25. PubMed ID: 25849223
    [Abstract] [Full Text] [Related]

  • 16. Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial.
    Hanania NA, Mannino DM, Criner GJ, Dransfield MT, Han MK, Jones CE, Kilbride S, Lomas DA, Martin N, Martinez FJ, Singh D, Wise RA, Halpin DMG, Lima R, Lipson DA.
    Chest; 2021 Mar 15; 159(3):985-995. PubMed ID: 33031829
    [Abstract] [Full Text] [Related]

  • 17. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
    Kerwin EM, Scott-Wilson C, Sanford L, Rennard S, Agusti A, Barnes N, Crim C.
    Respir Med; 2013 Apr 15; 107(4):560-9. PubMed ID: 23352226
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of fluticasone furoate/vilanterol (50/25 mcg; 100/25 mcg; 200/25 mcg) in Asian patients with chronic obstructive pulmonary disease: a randomized placebo-controlled trial.
    Zheng J, de Guia T, Wang-Jairaj J, Newlands AH, Wang C, Crim C, Zhong N.
    Curr Med Res Opin; 2015 Jun 15; 31(6):1191-200. PubMed ID: 25830381
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.
    Ferguson GT, Brown N, Compton C, Corbridge TC, Dorais K, Fogarty C, Harvey C, Kaisermann MC, Lipson DA, Martin N, Sciurba F, Stiegler M, Zhu CQ, Bernstein D.
    Respir Res; 2020 May 29; 21(1):131. PubMed ID: 32471423
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.